Diphenylbutylpiperidine
(Redirected from Diphenylbutylpiperazine)
Diphenylbutylpiperidines are a class of typical antipsychotic drugs which were all synthesized, developed, and marketed by Janssen Pharmaceutica.[1][2]
They include:
- Clopimozide (R-29,764)
- Fluspirilene (Redeptin)
- Penfluridol (Semap, Micefal, Longoperidol)
- Pimozide (Orap)
A closely related antipsychotic, amperozide, has an additional nitrogen atom in the heterocyclic ring and is classified as a diphenylbutylpiperazine.[3]
References
[edit]- ^ Galizzi JP, Fosset M, Romey G, Laduron P, Lazdunski M (October 1986). "Neuroleptics of the diphenylbutylpiperidine series are potent calcium channel inhibitors". Proceedings of the National Academy of Sciences of the United States of America. 83 (19): 7513–7. Bibcode:1986PNAS...83.7513G. doi:10.1073/pnas.83.19.7513. PMC 386749. PMID 2429309.
- ^ Qar J, Galizzi JP, Fosset M, Lazdunski M (September 1987). "Receptors for diphenylbutylpiperidine neuroleptics in brain, cardiac, and smooth muscle membranes. Relationship with receptors for 1,4-dihydropyridines and phenylalkylamines and with Ca2+ channel blockade". European Journal of Pharmacology. 141 (2): 261–8. doi:10.1016/0014-2999(87)90271-8. PMID 2445589.
- ^ Figueras, Albert; Capellà, Dolors (1993). Antipsychotic drugs. Side Effects of Drugs Annual. Vol. 17. pp. 49–71. doi:10.1016/S0378-6080(05)80189-8. ISBN 978-0-444-82005-1.